Advancing Cell-Based Therapies

Advancing targeted cell therapies for complex and life-threatening diseases.

Artistic circles in abstract design

Our Scientific Foundation

Ayma Therapeutics, Inc is a clinical-stage biotechnology company focused on developing novel red blood cell–based therapies. Our approach combines established pharmacology with advanced cell encapsulation techniques to enable controlled, targeted drug delivery for serious cardiovascular and infectious diseases.

Our Cell Therapy Platform

Our proprietary technology encapsulates small-molecule drugs inside a patient’s own red blood cells. This approach is designed to improve pharmacokinetics, enhance drug tolerability, and enable sustained delivery to affected tissues, particularly the lungs and cardiovascular system.

Cell being injected under microscope

Targeted Therapies in Clinical Development

  • AYX programs leverage red cell delivery to optimize drug performance.
  • Focused on ARDS, cardiovascular disease, and inflammatory conditions.
  • Over 500 patients dosed, validating our therapeutic approach.

Guided by Industry and Clinical Experts

  • Led by experts in pharmacology, genetics, medicine, and biotechnology.
  • Advisory board includes leaders from NIH, Mayo Clinic, and academia.
  • Deep experience across drug development, trials, and commercialization.

Innovation Built for Clinical Impact

Our cell-based platform is developed to improve drug delivery, safety, and outcomes in complex diseases. Reach out to explore our therapies, trials, and scientific approach.

Connect With Our Team